Betta Pharmaceuticals Co Ltd

Betta Pharmaceuticals released its 2026 interim report, with net profit attributable to the parent company of 302 million yuan, up 115.97% from the same period last year. Total operating revenue was 1.976 billion yuan, an increase of 245 million yuan from the same period last year, up 14.12% year-on-year, marking five consecutive years of growth. Net cash inflow from operating activities was 412 million yuan, a decrease of 32.6386 million yuan from the same period last year, down 7.33% year-on-year. The company's latest asset-liability ratio was 35.56%, down 2.72 percentage points from the same period last year; the latest gross margin was 76.43%, down 4.75 percentage points from the same period last year; the latest return on equity was 4.56%, up 2.06 percentage points from the same period last year. Diluted earnings per share were 0.72 yuan, an increase of 0.39 yuan from the same period last year, up 118.18% year-on-year.

On the evening of July 22, multiple listed companies on the Shanghai and Shenzhen exchanges released important announcements. In terms of earnings, Yisheng Livestock & Poultry Breeding reported first-half net profit surged 4,897.29 percent year-on-year to 308 million yuan, and plans to distribute 1.5 yuan per 10 shares. Lianxun Instruments expects first-half net profit to rise between 801.96 percent and 925.75 percent year-on-year. China Southern Power Grid Digital expects net profit to increase between 1,051.24 percent and 1,511.74 percent year-on-year. Betta Pharmaceuticals expects net profit to grow between 120 percent and 180 percent year-on-year. Regarding major contracts, a controlled subsidiary of Jereh Group signed a gas turbine generator set supply contract worth 1.465 billion US dollars, accounting for approximately 61.33 percent of the company's 2025 audited revenue. A wholly-owned grand subsidiary of Jingang Photovoltaic signed an artificial intelligence computing power technical service contract worth 614 million yuan. A subordinate subsidiary of PowerChina signed a subcontract for a seawater desalination project water transmission system worth approximately 8.925 billion yuan. In addition, chairmen of companies including Wanhua Chemical, ArcSoft, and Hangyang proposed to implement interim dividends. Companies such as Biwin Storage, Daqin Railway, and Changjiang Securities disclosed share buyback plans. Trading in shares of Jiayun Technology and Lianchuang Electronics was suspended due to planned changes in control rights.

Betta Pharmaceuticals announced that the clinical trial application for a new indication of its self-developed targeted drug, Icotinib Hydrochloride Tablets, has been approved by the National Medical Products Administration. The indication is for postoperative adjuvant treatment of stage IA2 high-risk to stage IB non-small cell lung cancer with EGFR-sensitive mutations. Icotinib is China's first lung cancer targeted drug with independent intellectual property rights, and this marks the clinical trial application for its fourth indication.

Betta Pharmaceuticals announced that three of its products have been included in the National Essential Medicines List, 2026 edition. Among them, bevacizumab is a new addition, while icotinib and trastuzumab remain on the list. This inclusion reflects strong clinical recognition of the products' efficacy. Essential Medicines List products, supported by policies such as tiered diagnosis and treatment and medical consortium development, can achieve full coverage across medical institutions at all levels, further penetrate primary care, and significantly improve drug accessibility. This has a positive impact on boosting product sales. In the first quarter of 2026, Betta Pharmaceuticals achieved revenue of 1.04 billion yuan and net profit attributable to the parent company of 236 million yuan.

Betta Pharmaceuticals announced that the ELEVATE study of ensartinib as adjuvant therapy for stage IB to IIIB ALK-positive non-small cell lung cancer has been published in full in the New England Journal of Medicine, a top international medical journal. The study involved 56 medical centers in China and enrolled 274 patients. Results showed that the two-year disease-free survival rate was 86.4 percent in the ensartinib group and 53.5 percent in the placebo group, reducing the risk of disease recurrence or death by 80 percent. Ensartinib is a novel, potent, and highly selective next-generation ALK inhibitor. Its first- and second-line indications have been approved in China, and it was approved for marketing in the United States in December 2024. Currently, the marketing application for the adjuvant therapy indication of ensartinib in China has been accepted.